MARKET

SCPH

SCPH

scPharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.05
-0.17
-1.84%
Closed 16:00 12/01 EST
OPEN
9.32
PREV CLOSE
9.22
HIGH
9.33
LOW
8.91
VOLUME
60.76K
TURNOVER
--
52 WEEK HIGH
11.99
52 WEEK LOW
4.010
MARKET CAP
247.25M
P/E (TTM)
-5.5996
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions.
Benzinga · 3d ago
scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference
BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 3 at 11:20am EST. A live webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.About scPharmaceuticals scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.Katherine Taudvin scPharmaceuticals Inc., 781-301-6706 ktaudvin@scpharma.comInvestors: Hans Vitzthum LifeSci Advisors, 617-430-7578 hans@lifesciadvisors.comMedia: Kate Coyle ICR Inc., 203-682-8210 kate.coyle@icrinc.com
GlobeNewswire · 11/19 13:00
scPharmaceuticals Q3 EPS $(0.33), Same YoY
scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.33) per share. This is unchanged from the same period last year.
Benzinga · 11/16 12:08
scPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
scPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Zacks · 10/01 12:19
scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX® (furosemide) for subcutaneous administration
scPharmaceuticals to host a KOL call on an investigational drug for the outpatient treatment of congestion in patients with heart failure.
Business Wire · 09/17 12:00
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
scPharmaceuticals announced it will present at the virtual HC Wainwright Annual Global Investment and Cantor Fitzgerald Global Healthcare Conferences
Business Wire · 09/03 12:00
What Is The Ownership Structure Like For scPharmaceuticals Inc. (NASDAQ:SCPH)?
The big shareholder groups in scPharmaceuticals Inc. (NASDAQ:SCPH) have power over the company. Insiders often own a...
Simply Wall St. · 08/28 19:27
ScPharma inks supply agreement with West Pharma
Seeking Alpha - Article · 08/21 11:39
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SCPH. Analyze the recent business situations of scPharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SCPH stock price target is 13.75 with a high estimate of 15.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 74
Institutional Holdings: 20.46M
% Owned: 74.88%
Shares Outstanding: 27.32M
TypeInstitutionsShares
Increased
17
109.23K
New
12
-136.59K
Decreased
17
415.36K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.88%
Healthcare Equipment & Supplies
+1.48%
Key Executives
Chairman/Director
Jack A. Khattar
Chairman/Independent Director
Jack Khattar
President/Chief Executive Officer/Chief Financial Officer/Director
John Tucker
Senior Vice President - Finance/Chief Accounting Officer
Rachael Nokes
Independent Director
Mette Agger
Independent Director
Minnie Baylor-Henry
Independent Director
Sara Bonstein
Independent Director
Mason Freeman
Director
Mette Kirstine Agger
Director
Klaus Veitinger,
Independent Director
Frederick Hudson
Independent Director
M Schaeffer
Independent Director
Leonard Schaeffer
Independent Director
Klaus Veitinger
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SCPH
scPharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip. The Company's products administered subcutaneously through the sc2Wear Infusor. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. The Company has completed two pivotal clinical studies, four exploratory clinical studies, and 12 human factor studies for Furoscix, and scCeftriaxone an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Scpharmaceuticals Inc stock information, including NASDAQ:SCPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SCPH stock methods without spending real money on the virtual paper trading platform.